Despite challenges in the biopharma sector, Sophia Genetics SA (SOPH) showcases robust growth and strategic advancements in ...

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn .

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer, sending the biotech firm's shares surging more than twofold in premarket ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

Antibody-drug conjugates are currently being investigated in more than 260 clinical trials.“It’s going to be the next novel ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer in a late-stage study, sending the biotech firm's shares surging to a record ...

AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a year in a large study, a result that may lead to expanded use of the medicine.

CHICAGO — Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death ...

Common respiratory infections like COVID and the flu could awaken dormant breast cancer cells in the lungs and lead to ...

CHICAGO (Reuters) -Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or ...

He was in part referring to AstraZeneca's promising data shared at the 2025 American Society of Clinical Oncology annual meeting in Chicago, where several other companies also delivered positive ...